Floatz logo

Tsc-204-C0702

HPV-Associated Vaginal Adenocarcinoma

TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the HPV-Associated Vaginal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
e7 tcr-t cells
Christian Hinrichs
Phase 2CCC
Tsc-202-A0201
TScan Therapeutics, Inc.
Phase 1CC
Tsc-200-A0201
TScan Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

Tsc-204-C0702 is also rated in:

anogenital human papillomavirus infectionDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →